Additionally, Zhang et al. discovered that the stem cell properties of CD90+ liver cancer cells are regulated by the downstream signaling pathways of SHH/GLI and IL6/JAK2/STAT3, which can be modulated using the JAK2 inhibitor AZD1480 and interleukin-6 (IL6) neutralizing antibody [95]. The gene discussed is GLI1; the disease is liver cancer.